ketoconazole has been researched along with Fascioliasis in 3 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Fascioliasis: Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " hepatica, dosed orally with triclabendazole at a dosage of 10mg/kg live weight and ketoconazole at a dosage of 10mg/kg live weight." | 1.38 | Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole. ( Alvarez, LI; Brennan, GP; Devine, C; Fairweather, I; Hoey, E; Lanusse, CE; Trudgett, A, 2012) |
| " The first group was dosed orally with TCBZ at a dosage of 10mg/kg and KTZ at a dosage of 10mg/kg." | 1.37 | Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole. ( Alvarez, LI; Brennan, GP; Devine, C; Fairweather, I; Hoey, E; Lanusse, CE; Trudgett, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Devine, C | 3 |
| Brennan, GP | 3 |
| Lanusse, CE | 3 |
| Alvarez, LI | 3 |
| Trudgett, A | 3 |
| Hoey, E | 3 |
| Fairweather, I | 3 |
3 other studies available for ketoconazole and Fascioliasis
| Article | Year |
|---|---|
Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole.
Topics: Animals; Benzimidazoles; Drug Synergism; Drug Therapy, Combination; Fasciola hepatica; Fascioliasis; | 2011 |
Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
Topics: Animals; Anthelmintics; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2011 |
Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
Topics: 14-alpha Demethylase Inhibitors; Animals; Anthelmintics; Benzimidazoles; Drug Resistance; Drug Syner | 2012 |